Abbott’s Cell-Dyn Sapphire Gets FDA Clearance
Abbott has received 510(k) clearance from the FDA for its automated, high-volume hematology instrument, the CELL-DYN Sapphire – the latest CELL-DYN hematology analyzer to incorporate monoclonal antibody tests for additional cellular analysis.
Advanced Cell Technology and The Burnham Institute Announce Collaboration to Isolate Stem Cell-Specific Differentiation Markers
Advanced Cell Technology, Inc. announced today it has entered into a research collaboration agreement with the The Burnham Institute, a California based non-profit medical research institution, to conduct research that aims to isolate stem cell specific differentiation markers.
Bio-Matrix Scientific Signs Letter of Intent to Acquire Former American Red Cross Facility for Its New Stem Cell Bank and Research Center
Bio-Matrix Scientific Group Inc. announced today that it has signed a letter of intent on the long-term lease of a facility formerly operated by the American Red Cross.
Chemicon International, Inc. Enters into a License to Commercialize Research Products Utilizing Human Embryonic Stem Cell Technology from Wisconsin Alumni Research Foundation (WARF)
Serologicals Corporation announced today that Chemicon International, Inc., its wholly-owned subsidiary based in Temecula, CA, and the Wisconsin Alumni Research Foundation (WARF) have signed a license to commercialize research products derived from patented human embryonic stem (ES) cell technology.
Data Safety Monitoring Board Recommends Continuation of MyVax(R) Personalized Immunotherapy Pivotal Phase 3 Trial for Treatment of Follicular Non-Hodgkin’s Lymphoma
Genitope Corporation today announced that its independent Data Safety Monitoring Board (DSMB) reviewed the first planned interim analysis of data for efficacy in its pivotal Phase 3 clinical trial for treatment of follicular non-Hodgkin’s Lymphoma (fNHL) and recommended that the trial continue as planned.
Bone Graft Clinical Trial Expanded
Aastrom Biosciences announced that it has expanded the U.S. Phase I/II clinical trial of its adult stem cell-based Tissue Repair Cells (TRCs) in the treatment of severe long bone open or non-union fractures to include the University of Nebraska Medical Center (UNMC) in Omaha, Neb.
GenVec Appoints Thomas A. Davis, M.D., Chief Medical Officer; Will Lead Clinical Development of Company’s Product Candidates
GenVec, Inc. today announced that Thomas A. Davis, M.D., has joined the company as its chief medical officer. Dr. Davis will be responsible for directing the clinical development of GenVec’s growing portfolio of gene-based therapies for the treatment of cancer, cardiovascular disease and diseases of the eye.
GammaCan Reports on Patient Enrollment in Phase II Clinical Trial
GammaCan International, a developer of immunotherapies for cancer, today announced that the Phase II clinical trial of GCAN 101 for the treatment of metastatic melanoma, prostate and/or colon cancers is underway.
Invitrogen to Acquire BioSource for $130M
Invitrogen Corp., a maker of products used in gene cloning and analysis, on Tuesday said it has agreed to acquire BioSource International Inc. for $130 million in cash.
Kirin Brewery Co., Ltd. To Acquire Hematech – Aims To Accelerate Development Of Fully Human Polyclonal Antibody Medicines
Through this acquisition, Kirin has acquired Hematech’s core technology and research infrastructure for production of bovine-derived human polyclonal antibodies.
PhereSys Therapeutics Announces Consulting Agreement with Advanced Cell & Gene Therapy, LLC
PhereSys(TM) Therapeutics Corporation announced today that it has entered into a comprehensive consulting services agreement with Advanced Cell & Gene Therapy LLC (“ACGT”), Scott R. Burger, MD, Principal.
Pall Awarded Long-Term Contract from American Red Cross for Leukoreduction Filter Systems
Pall Corporation announced today the signing of a new long-term agreement with the American Red Cross (ARC) to provide blood collection systems incorporating its proprietary filtration and venting technology.
Oxford BioMedica is Awarded Grant for Monudin(R) From the Motor Neurone Disease Association
Oxford BioMedica, the leading gene therapy company, announced today that the UK Motor Neurone Disease (MND) Association has awarded a research grant to support preclinical evaluation of MoNuDin for the treatment of Amyotrophic Lateral Sclerosis (ALS), the most common form of motor neurone disease.
Spanish Biotechnology Company, Cellerix, Receives Orphan Status Designation By The European Medicines Evaluation Agency For A Stem Cell Medicinal Product
Cellerix, a company belonging to the Genetrix group and specialised in the development of cell-based therapies, has received Orphan Status designation by the European Medicines Evaluation Agency (EMEA) for one of its products in development. Cellerix’s medicinal product is currently in clinical trials and uses stem cells taken from adipose tissue coming from the same patient, and will be used for the treatment of fistulas.
StemCell Treatment Center to Open in Las Vegas
StemCell Pharma Inc. announces the opening Oct. 3, 2005 of the StemCell Treatment Center of Las Vegas, where the placenta/stem cell implant developed by Alfred T. Sapse, M.D. (ret), will be used.
StemCell Technologies Brings Design and Production of RoboSep(TM) Back to Canada
StemCell Technologies, Inc. announced today that StarFish Medical (Victoria, BC) has been chosen to finish the design work and to be the responsible manufacturer of the RoboSep™, the first instrument to offer true walk-away automation of magnetic cell separation.
US Patents Victory for Stem Cell Sciences
Scottish biotech Stem Cell Sciences has won important extensions to its US patent rights which it expects to boost revenues in the critical American pharmaceuticals market.
Malachite Management has joined forces with established and reputable authors and publishers to bring you the following market reports outlining the very latest in Cell Therapy, Gene Therapy, and Immunotherapeutic approaches to Cancer.
“Cell Therapy – Technologies, Markets, and Companies” is over 400 pages of the basic technologies, clinical applications, market analysis, and company profiles related to the cell therapy industry worldwide.
For more information, including order forms, please see:
Cell Therapy Report Summary
Cell Therapy Sample Chapter
Cell Therapy Table of Contents Vol. 1 Vol. 2
Cell Therapy Order Form
“Gene Therapy – Technologies, Markets, and Companies” is over 500 pages of the basic technologies, clinical applications, market analysis, and company profiles related to the gene therapy industry worldwide.
For more information, including order forms, please see:
Gene Therapy Report Summary
Gene Therapy Table of Contents Vol. 1 Vol. 2
Gene Therapy Order Form
The Immunotherapy Reports cover the most recent developments in the immunotherapeutic approaches to cancer.
A Shift in Cancer Immunotherapy Strategies?
Immunotherapy Strategies Executive Summary
Immunotherapy Strategies Table of Contents
Future Perspectives in Cancer Immunotherapy
Future Perspectives Executive Summary
Future Perspectives Table of Contents